Here is more from the research and data they found in their test run:

In some patients, the improvements were striking. Although all had aggressive, inoperable malignant melanoma, those treated with the virus therapy – known as T-VEC – at an earlier stage survived on average 20 months longer than patients given an alternative.

In other patients results were more modest, but the study represents a landmark: it is the first, large, randomised trial of a so-called oncolytic virus to show success.

Cancer scientists predict it will be the first of many in the coming years – adding a new weapon to our arsenal of cancer treatments.

The method – known as viral immunotherapy – works by launching a “two-pronged attack” on cancer cells. The virus is genetically modified so that it can’t replicate in healthy cells – meaning it homes in on cancer cells.

This is remarkable and we hope this turns into a big leap forward in the war on cancer.

thanks to independent.co.uk for the great info